StockData
Vaxcyte, Inc. logo

Vaxcyte, Inc. (PCVX) stock

PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$59.40−2.21 (-3.59%)

Close on Nov 17, 2026Market cap $8.84BP/E –Yield 0.00%

Vaxcyte shares outstanding

Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.

Vaxcyte's shares outstanding was 144M at Jun 30, 2026. For fiscal 2025 it was 136M, up 11.6% from the year before. The highest annual figure on record is 136M in fiscal 2025.

Annual shares outstanding

PeriodPeriod endValueChange
FY2025Dec 31, 2025136M+11.6%
FY2024Dec 31, 2024122M+25.6%
FY2023Dec 31, 202397M+49.8%
FY2022Dec 31, 202265M+25.0%
FY2021Dec 31, 202152M+75.7%
FY2020Dec 31, 202030M+678.5%
FY2019Dec 31, 20194M+4.6%
FY2018Dec 31, 20184M–

Quarterly shares outstanding

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026144M+6.2%
Q1 FY2026Mar 31, 2026140M+2.8%
Q4 FY2025Dec 31, 2025136M+0.9%
Q3 FY2025Sep 30, 2025136M+10.1%
Q2 FY2025Jun 30, 2025136M+16.0%
Q1 FY2025Mar 31, 2025136M+21.5%
Q4 FY2024Dec 31, 2024135M+31.9%
Q3 FY2024Sep 30, 2024124M+21.7%
Q2 FY2024Jun 30, 2024117M+19.6%
Q1 FY2024Mar 31, 2024112M+29.6%
Q4 FY2023Dec 31, 2023103M+29.8%
Q3 FY2023Sep 30, 2023102M+64.0%
Q2 FY2023Jun 30, 202398M+61.2%
Q1 FY2023Mar 31, 202386M+49.8%
Q4 FY2022Dec 31, 202279M+49.6%
Q3 FY2022Sep 30, 202262M+18.8%
Q2 FY2022Jun 30, 202261M+18.1%
Q1 FY2022Mar 31, 202258M+12.5%
Q4 FY2021Dec 31, 202153M+3.6%
Q3 FY2021Sep 30, 202152M+2.5%
Q2 FY2021Jun 30, 202152M+336.4%
Q1 FY2021Mar 31, 202151M+1163.6%
Q4 FY2020Dec 31, 202051M+1185.3%
Q3 FY2020Sep 30, 202051M+1219.5%
Q2 FY2020Jun 30, 202012M+220.5%
Q1 FY2020Mar 31, 20204M+10.3%
Q4 FY2019Dec 31, 20194M–
Q3 FY2019Sep 30, 20194M–
Q2 FY2019Jun 30, 20194M–
Q1 FY2019Mar 31, 20194M–

More Vaxcyte figures

See a number that looks wrong?